KTX 0101

Drug Profile

KTX 0101

Alternative Names: Sodium beta-hydroxybutyrate

Latest Information Update: 27 Sep 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG
  • Developer KetoCytonyx
  • Class Ketone bodies; Neuroprotectants; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cognition disorders

Most Recent Events

  • 27 Sep 2011 No development reported - Phase-I for Cognition disorders in United Kingdom (IV)
  • 14 Dec 2004 Preclinical data from a media release have been added to the adverse events, pharmacodynamic and pharmacokinetic sections
  • 13 Dec 2004 KetoCytonyx has completed a phase I trial in Cognition disorders in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top